Drugs / CEPEGINTERFERON ALFA-2B
CEPEGINTERFERON ALFA-2B
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01740089 | Nov 2011 → Jul 2012 | hepatitis C virus infection | Biocad | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01889433 | Jul 2013 → Dec 2015 | hepatitis C virus infection | Biocad | Completed | No outcome recorded |
| Phase 3 | NCT02103439 | Jun 2013 → Aug 2015 | hepatitis C virus infection | Biocad | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEPEGINTERFERON ALFA-2B | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108064 ↗ |
| Known as | Algeron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01740089 ↗ |
| Known as | Pegylated human interferon a-2b | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108064 ↗ |
| Route | Subcutaneous | “1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously” NCT01740089 ↗ |